AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 51 min read$TEVA

Hughes Eric A sold $892K of TEVA

Hughes Eric A (See "Remarks") sold 25,578 shares of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) at $34.88 ($0.89M total) on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hughes Eric A
Published Aug 5, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:26 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TEVA
Neutral
medium confidence
Mentioned
$TEVA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEVANeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider activity but does not include new fundamentals, guidance, litigation, or operational changes.

02

Market read

Traders may note insider selling, but the 10b5-1 structure makes it a low-conviction catalyst.

03

What to watch

Insider sales can be routine for diversification or tax planning; without additional context (e.g., option exercises, other concurrent filings), directional inference is weak.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-05, transaction dated 2026-08-03

Background

SEC Form 4 insider transaction for TEVA, reported as an open-market sale by an officer under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$TEVANeutralMedium confidence
Context

TEVA insider Form 4 shows Hughes Eric A sold 25,578 shares at $34.8757 on 2026-08-03 under a 10b5-1 plan.

Expected impact

Limited near-term impact; any effect is likely sentiment-only and outweighed by the plan structure.

Evidence & confidence

The filing is primary-source and time-stamped, but the transaction is explicitly under a pre-arranged 10b5-1 plan, reducing interpretive value versus unscheduled sales.

Market effects

Sector

No clear sector read-through from a single 10b5-1 insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could be purely liquidity-driven and not a bearish signal, especially given the pre-arranged 10b5-1 plan.

Key entities

  • issuer
    TEVA PHARMACEUTICAL INDUSTRIES LTD

    Subject of the Form 4 insider sale disclosure.

  • insider
    Hughes Eric A

    Officer who sold 25,578 shares at $34.8757 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEVA insider trading history →

Related articles

SEP 4
$TEVAMed

S&P upgrades Teva rating on deleveraging and pipeline strength

S&P Global Ratings upgraded Teva Pharmaceutical Industries Ltd. to 'BBB-' from 'BB+', citing strong branded products, generics stabilization, and debt reduction. Teva's key brands generated $3.1B in 2025, with expected growth. The company reduced debt from $29B in 2018 to $17B in 2025 and aims for mid-3x leverage by year-end. S&P forecasts strong cash flow and debt reduction.

investing.com2 min
SEP 4
$TEVAMed

Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

Teva Pharmaceuticals (TEVA) agreed to a stalking-horse bid of up to $125M for BioXcel Therapeutics' (BTAI) assets, including $57.5M in cash and up to $67.5M in contingent payments. The deal, subject to court approval, includes IGALMI and other assets. The FDA has a 2026 target date for a supplemental application to expand IGALMI's label to at-home use. Competing bids may arise.

finance.yahoo.com3 min
SEP 4
$TEVAMed

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

S&P Global Ratings upgraded Teva Pharmaceutical's long-term issuer credit rating to BBB- from BB+, reflecting strong financial performance and debt reduction. This is the third upgrade in recent months, with Teva now holding investment-grade ratings from all major agencies. The company's CFO attributed the upgrades to successful execution of its growth strategy and improved financial profile.

globenewswire.com1 min
SEP 2
$TEVAMedAI 8/10

Teva Stock Drops As Celiac Trial Fails To Impress - TipRanks.com

Teva Pharmaceutical's (TEVA) stock declined despite early-stage positive results from a Phase 2a trial of TEV-408 for celiac disease. Investors were unimpressed due to the lack of later-stage data or a commercialization timeline. The company is focusing on specialty medicines and biosimilars to stabilize growth but faces challenges from debt and generic revenue pressure.

tipranks.com2 min
SEP 2
$TEVAMedAI 8/10

Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trial

Teva Pharmaceutical Industries' experimental drug TEV-53408 met its main goal in a mid-stage trial, preventing intestinal damage in celiac disease patients. The Phase 2a study showed significant improvement in intestinal health and symptom scores compared to placebo. Teva plans further studies and projects peak sales of $1.5B-$2B for the drug, which targets the IL-15 pathway. The company has a deal with Royalty Pharma for up to $500M in support.

medcitynews.com2 min